PHE News

Precision for Value Acquires Redwood Outcomes

Redwood Outcomes strengthens Precision's existing health economic and outcomes research capabilities, adding extensive experience in epidemiology, statistics, meta-analysis, and decision modeling.

Precision for Value has acquired Redwood Outcomes, a leading international health economics and outcomes research (HEOR) company. Redwood Outcomes will be integrated into Precision Health Economics, adding new world-class scientific capabilities and significantly expanding Precision's global offering.


Precision's Jena to Participate in Upcoming AEI Forum

Principal Consultant Anupam Jena has been invited by the AEI to participate in a upcoming forum: "Rethinking the storyline for defensive medicine and medical liability: Causes, effects, and remedies."  The forum will be held on December 2nd, 2015 from 3:30-5:00pm ET at the AEI in Washington DC.


Precision's Becker Quoted in Roll Call

Precision for Medicine’s Karen Becker has been quoted in the latest edition of Roll Call, as Congress considers regulation of Lab-Developed Tests.  


Goldman in Modern Healthcare: Drop Medicaid 'Best Price' Rules

In the latest edition of Modern Healthcare, Precision's Dana Goldman addresses Medicaid's "best price" rules, suggesting a value-based strategy.


Philipson Quoted in Bloomberg BNA's Health Care Policy Report

Precision's Tomas Philipson, along with Scientific Advisor Seth Seabury, are featured in the just-released Bloomberg BNA Health Policy Report.

  • Academic Insights at

    the Speed of Business

  • Intellectual Integrity

    Led by professors at elite research universities, we bring intellectual integrity, academic rigor, and a creative approach to the most challenging problems in heath care.

  • Real World Impact

    PHE recommendations have defined and changed national and international payment policies.

  • Unparalleled Influence

    We frequently appear in top-tier publications and media outlets-- our work reaches top decision makers and influences outcomes.

  • Evidence Generation and

    Commercial Excellence

    As part of Precision for Value, our academic approach to research can be linked with a tailored, commercial approach that demonstrates the value of innovative medications.

  • Academic Insights at

    the Speed of Business